World News

New needle-free Covid vaccine given by a jet of air

New needle-free Covid vaccine given by a jet of air could ensure ‘wide-ranging protection’ against variants and future coronaviruses

  • Vaccine is being trialled by the University of Southampton
  • It uses a jet of air to push it through the skin rather than a needle
  • Technology aims to predict how the virus could mutate, allowing it to target emerging variants  

A new needle-free Covid vaccine that uses a jet of air to push it through the skin could give ‘wide-ranging protection’ against variants and future coronaviruses.

The vaccine, developed by Professor Jonathan Heeney of the University of Cambridge with research firm DIOSynVax, is being trialled by the University of Southampton.

The University of Southampton has developed the new vaccine which uses a jet of air to push it through the skin rather than a needle.

The technology it uses aims to predict how the virus could mutate, allowing it to target emerging variants.

The University of Southampton has developed the new vaccine which uses a jet of air to push it through the skin rather than a needle (pictured)

Professor Heeney said: ”As new variants emerge and immunity begins to wane we need newer technologies.

‘It’s vital that we continue to develop new generation vaccine candidates ready to help keep us safe from the next virus threats.

‘Our vaccine is innovative both in the way it primes the immune system to respond with a broader protective response, and how it is delivered. It is the first step towards a universal coronavirus vaccine.

‘Crucially, it is the first step towards a universal coronavirus vaccine we are developing, protecting us not just from Covid-19 variants but from future coronaviruses.’ 

Saul Faust, clinical chief investigator and director of the NIHR Southampton Clinical Research Facility, said: ‘This isn’t simply ‘yet another’ coronavirus vaccine as it has both Covid-19 variants and future coronaviruses in its sights.

‘This technology could give wide-ranging protection to huge numbers of people worldwide.’

While most existing Covid-19 vaccines use the sequence of the RNA for the spike protein from the first samples of the virus found in January 2020, the DIOSvax technology used for the new vaccine aims to predict how the virus could mutate, allowing it to target emerging variants. 

Volunteers from the Southampton area who have had two doses of an existing vaccine but not a booster are being sought for the trial for which they will be paid £785.

Volunteers from the Southampton area who have had two doses of an existing vaccine but not a booster are being sought for the trial for which they will be paid £785

Source: Read Full Article